Vaccine Studies in HIV-infected Subjects

HIV 感染者的疫苗研究

• 批准号: 7592410
• 负责人: Barney Scott Graham
• 金额: $ 31.49万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7592410
• 关键词: Adverse effects; Anti-Retroviral Agents; DNA; Educational Materials; Eligibility Determination; Enrollment; Goals; HIV vaccine; HIV-1; HIV-1 vaccine; Immune response; Immunotherapeutic agent; Individual; Infection; Infection Control; Medication Management; Numbers; Phase; Phase I Clinical Trials; Recruitment Activity; Screening Result; Therapeutic; Therapeutic Studies; Treatment Protocols; Vaccines; design

VRC 100 is designed to recruit and screen HIV-infected subjects for therapeutic HIV vaccines, as well as other vaccines to be developed for use in HIV-infected individuals. The results of this screening study will be used to determine if the subject meets eligibility requirements for participation in Phase I trials of investigational vaccines. Educational materials on vaccines are reviewed with and provided to subjects before enrollment into a study. VRC 101 is the first Phase I therapeutic study of two candidate HIV-1 vaccines developed by VRC and administered in a prime-boost regimen.

VRC 100旨在招募和筛查HIV感染的受试者，用于治疗性HIV疫苗，以及用于在HIV感染者中使用的其他疫苗。这项筛查研究的结果将用于确定受试者是否满足参与研究疫苗I期试验的资格要求。在入学研究之前，对疫苗的教育材料进行了审查并提供给受试者。 VRC 101是VRC开发的两种候选HIV-1疫苗的第一阶段治疗研究，并在促进方案中给药。